Methotrexate Monitoring in Patients with Renal or Liver Disease

Baseline Assessment and Monitoring

The American Academy of Dermatology recommends that patients with pre-existing renal or liver disease on methotrexate require intensified monitoring with CBC, liver function tests, and renal function tests every 2-4 weeks initially, then monthly for the first 6 months, followed by every 1-3 months thereafter, with mandatory folic acid supplementation and consideration of a test dose before full therapeutic dosing 1, 2
Baseline assessment should include complete blood count with differential and platelet count, comprehensive metabolic panel, liver function tests, hepatitis B and C serologies, non-invasive liver fibrosis assessment, chest X-ray, and pregnancy test in women of childbearing potential 1, 2, 3, 4
Baseline liver biopsy is not recommended, regardless of risk factors for hepatotoxicity 1, 4

The American Academy of Dermatology recommends CBC with differential, liver function tests, and renal function tests every 2-4 weeks during the initial phase, monthly during the stabilization phase, and every 1-3 months during the maintenance phase 1, 2, 3
Monitoring should be adjusted after dose increases, with a return to every 2-4 weeks monitoring for at least 6 weeks 1, 2

The American Academy of Dermatology recommends holding methotrexate if white blood cell count is <3.0 × 10⁹/L, absolute neutrophil count is <1.0-2.0 × 10⁹/L, platelet count is <100 × 10⁹/L, or mean corpuscular volume is >105 fL 1, 2, 3
Liver function tests should not be checked within 2 days of methotrexate dose, and methotrexate should be held if ALT/AST persistently >2-3 times upper limit of normal 1, 2, 5
Methotrexate should be discontinued if ALT/AST >5 times upper limit of normal 5

The American Academy of Dermatology recommends that all patients on methotrexate receive folic acid supplementation, 1-5 mg daily, taken 6 days per week, to reduce gastrointestinal, hepatic, and hematologic toxicity 1, 2, 3, 5

The American Academy of Dermatology recommends avoiding methotrexate in patients on dialysis, and using NSAIDs, trimethoprim-sulfamethoxazole, penicillins, and other hepatotoxic medications with caution 2, 3, 6

Methotrexate should be temporarily held for acute intercurrent illness, active infection, significant elevation in liver function tests, or hematologic abnormalities 1, 2, 4, 5
Methotrexate should be permanently discontinued for persistent liver function test abnormalities, development of pulmonary symptoms, or severe pancytopenia or bone marrow suppression 2, 3, 5, 7

The American College of Rheumatology recommends monitoring every 3-4 months after initial stabilization in patients without organ dysfunction, but a more intensified schedule is critical for patients with renal impairment, as it reduces methotrexate clearance and increases toxicity risk 8
For patients with pre-existing liver or kidney disease, the monitoring frequency differs substantially from standard protocols, with CBC, liver function tests, and renal function tests every 2-4 weeks initially, then monthly for the first 6 months, followed by every 1-3 months thereafter 8

The management algorithm for elevated liver enzymes includes decreasing the dose or temporarily withholding methotrexate if ALT/AST >2× upper limit of normal, and discontinuing methotrexate if ALT/AST >3× upper limit of normal despite dose reduction or if ALT/AST >5× upper limit of normal 8
For patients with pre-existing liver disease, consider additional monitoring with non-invasive fibrosis assessment and referral to gastroenterology or hepatology for vibration-controlled transient elastography if results suggest greater than minimal fibrosis 8